Tech Session V: Nanomedicine and Nanoscale Delivery (Focus: Nano)
Sustained heme-albumin release as a potential therapy for dry age-related macular degeneration
Thursday, July 17, 2025
10:54 AM - 11:05 AM EDT
Location: 120 B/C
Introduction: Age-related macular degeneration (AMD) is a leading cause of vision loss. Reactive Oxygen Species (ROS) have been implicated in playing a key role in the pathogenesis of dry AMD (dAMD). There is no cure and treatment options require frequent intravitreal injections. To target dAMD and mitigate disease progression, a novel anti-inflammatory heme-bound human serum albumin (heme-albumin) complex was investigated. The objective of this study was to evaluate a redox-responsive polydopamine (PDA) nanoparticle (NP) based drug delivery system for sustained release of heme-albumin in vitro and in vivo.
Learning Objectives:
At the completion of this activity, participants will know
Examine the ability to sustain release of heme-albumin from polydopamine nanoparticles
Determine the action of heme-albumin on the retina
Amna Abdalbaqi, MS – Graduate Research Assistant, Chemical and Biomolecular Engineering, The Ohio State University; Megan Allyn, MS – Graduate Research Assistant, Chemical and Biomolecular Engineering, The Ohio State University; Nagaraj Kerur, DVM, PhD – Associate Professor, Ophthalmology and Visual Sciences, The Ohio State University; Matthew Ohr – Professor and Retina Division Director, Ophthalmology and Visual Sciences, The Ohio State University; Andre Palmer – Professor and Fenburr Ohio Eminent Scholar, Chemical and Biomolecular Engineering, The Ohio State University
